SCYNEXIS Reports Results From Phase 1 Study Of SCY-247, Second-Gen Triterpenoid Antifungal Under Development For Treatment And Prevention Of Invasive Fungal Infections

Author: Benzinga Newsdesk | September 30, 2025 07:07am

• No safety concerns or dose limiting toxicities observed
• SCY-247 was able to achieve target exposures at doses lower than our first-generation fungerp
• Safety, tolerability, and pharmacokinetic profile support the continued clinical development of SCY-247

JERSEY CITY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced positive results from a Phase 1 study of SCY-247, its second-generation triterpenoid antifungal under development for the treatment and prevention of invasive fungal infections with the potential to provide the therapeutic advantages of both an oral and IV formulation.

Posted In: SCYX